US2940972A
(en)
|
1957-06-27 |
1960-06-14 |
Thomae Gmbh Dr K |
Tri-and tetra-substituted pteridine derivatives
|
GB1583753A
(en)
|
1976-07-14 |
1981-02-04 |
Science Union & Cie |
Piperidine derivatives processes for their preparation and pharmaceutical compositions containing them
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
GB9125001D0
(en)
|
1991-11-25 |
1992-01-22 |
Ici Plc |
Heterocyclic compounds
|
TW219935B
(en)
|
1991-12-25 |
1994-02-01 |
Mitsubishi Chemicals Co Ltd |
|
US5843941A
(en)
|
1993-05-14 |
1998-12-01 |
Genentech, Inc. |
Ras farnesyl transferase inhibitors
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
CA2262403C
(en)
|
1995-07-31 |
2011-09-20 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
TW472045B
(en)
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
BR9809501A
(en)
|
1997-05-28 |
2000-06-20 |
Rhone Poulenc Rorer Pharma |
Compound, pharmaceutical composition, and processes to inhibit tyrosine kinase activity pdgf, to inhibit tyrosine kinase lck activity, to inhibit cell proliferation, differentiation or mediator release in a patient, to treat a pathology linked to a hyperproliferative disorder , to treat restenosis, and, to treat inflammation in a patient
|
US6235740B1
(en)
|
1997-08-25 |
2001-05-22 |
Bristol-Myers Squibb Co. |
Imidazoquinoxaline protein tyrosine kinase inhibitors
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
AU3033500A
(en)
|
1999-01-15 |
2000-08-01 |
Agouron Pharmaceuticals, Inc. |
Non-peptide glp-1 agonists
|
CN1178932C
(en)
|
1999-03-17 |
2004-12-08 |
阿斯特拉曾尼卡有限公司 |
Amide derivatives
|
WO2001019825A1
(en)
|
1999-09-15 |
2001-03-22 |
Warner-Lambert Company |
Pteridinones as kinase inhibitors
|
DE10013318A1
(en)
|
2000-03-17 |
2001-09-20 |
Merck Patent Gmbh |
Quinoxaline derivatives are used as photo-stable UV filters in cosmetic or pharmaceutical sunscreens for the hair or skin
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
US20030114448A1
(en)
|
2001-05-31 |
2003-06-19 |
Millennium Pharmaceuticals, Inc. |
Inhibitors of factor Xa
|
ES2295441T3
(en)
|
2001-12-18 |
2008-04-16 |
MERCK & CO., INC. |
MODULATORS OF PIRAZOL HETEROARIL REPLACED 5 METABOTROPIC RECEIVER OF GLUTAMATE.
|
DK1463506T3
(en)
|
2001-12-24 |
2010-01-11 |
Astrazeneca Ab |
Substituted quinazoline derivatives as inhibitors of aurora kinases
|
JP2003213463A
(en)
|
2002-01-17 |
2003-07-30 |
Sumitomo Chem Co Ltd |
Metal anticorrosive and cleaning solution
|
WO2003076416A1
(en)
|
2002-03-08 |
2003-09-18 |
Warner-Lambert Company Llc |
Oxo azabicyclic compounds
|
EP1496896A4
(en)
|
2002-04-08 |
2007-10-31 |
Merck & Co Inc |
Inhibitors of akt activity
|
US20040097725A1
(en)
|
2002-07-10 |
2004-05-20 |
Norman Herron |
Charge transport compositions and electronic devices made with such compositions
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
KR20050056227A
(en)
|
2002-10-03 |
2005-06-14 |
탈자진 인코포레이티드 |
Vasculostatic agents and methods of use thereof
|
AR043059A1
(en)
|
2002-11-12 |
2005-07-13 |
Bayer Pharmaceuticals Corp |
DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS
|
US7098332B2
(en)
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
WO2004065378A1
(en)
|
2003-01-17 |
2004-08-05 |
Warner-Lambert Company Llc |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
EP1620413A2
(en)
|
2003-04-30 |
2006-02-01 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
CA2525547C
(en)
|
2003-05-14 |
2012-07-03 |
Torreypines Therapeutics, Inc. |
Compounds and uses thereof in modulating amyloid beta
|
NZ544112A
(en)
|
2003-05-23 |
2010-01-29 |
Zentaris Gmbh |
Novel pyridopyrazines and use thereof as kinase modulators
|
DE10323345A1
(en)
|
2003-05-23 |
2004-12-16 |
Zentaris Gmbh |
New pyridopyrazines and their use as kinase inhibitors
|
WO2005007099A2
(en)
|
2003-07-10 |
2005-01-27 |
Imclone Systems Incorporated |
Pkb inhibitors as anti-tumor agents
|
CA2533417A1
(en)
|
2003-07-21 |
2005-02-03 |
Mitchell A. Avery |
Design and synthesis of optimized ligands for ppar
|
KR20060054410A
(en)
|
2003-08-01 |
2006-05-22 |
제네랩스 테크놀로지스, 인코포레이티드 |
Bicyclic imidazol derivatives against flaviviridae
|
PL1673092T3
(en)
|
2003-10-17 |
2008-01-31 |
4 Aza Ip Nv |
Heterocycle-substituted pteridine derivatives and their use in therapy
|
CA2543820C
(en)
|
2003-11-07 |
2012-07-10 |
Chiron Corporation |
Methods for synthesizing quinolinone compounds
|
KR101118582B1
(en)
|
2003-11-20 |
2012-02-27 |
얀센 파마슈티카 엔.브이. |
6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as polyadp-ribosepolymerase inhibitors
|
KR100861515B1
(en)
|
2003-11-24 |
2008-10-02 |
에프. 호프만-라 로슈 아게 |
Pyrazolyl and imidazolyl pyrimidines
|
AU2004303602C1
(en)
|
2003-12-23 |
2009-05-28 |
Astex Therapeutics Limited |
Pyrazole derivatives as protein kinase modulators
|
US7098222B2
(en)
|
2004-05-12 |
2006-08-29 |
Abbott Laboratories |
Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
|
US7205316B2
(en)
|
2004-05-12 |
2007-04-17 |
Abbott Laboratories |
Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
|
EP1789399A1
(en)
|
2004-08-31 |
2007-05-30 |
AstraZeneca AB |
Quinazolinone derivatives and their use as b-raf inhibitors
|
AU2005293835A1
(en)
|
2004-10-14 |
2006-04-20 |
F. Hoffmann-La Roche Ag |
1,5-Naphthyridine azolidinones having CDK1 antiproliferative activity
|
JP2008516939A
(en)
|
2004-10-15 |
2008-05-22 |
アストラゼネカ アクチボラグ |
Chemical compound
|
SI1830869T1
(en)
|
2004-12-24 |
2013-12-31 |
Spinifex Pharmaceuticals Pty Ltd |
Method of treatment or prophylaxis
|
NZ556686A
(en)
|
2005-02-14 |
2010-01-29 |
Bionomics Ltd |
Novel tubulin polymerisation inhibitors
|
WO2006092430A1
(en)
|
2005-03-03 |
2006-09-08 |
Universität des Saarlandes |
Selective inhibitors of human corticosteroid synthases
|
JP2008540535A
(en)
|
2005-05-12 |
2008-11-20 |
メルク エンド カムパニー インコーポレーテッド |
Tyrosine kinase inhibitor
|
AU2006247315A1
(en)
|
2005-05-18 |
2006-11-23 |
Wyeth |
4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
KR20080049767A
(en)
|
2005-08-26 |
2008-06-04 |
라보라뚜와르 세로노 에스. 에이. |
Pyrazine derivatives and use as pi3k inhibitors
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
EP1790342A1
(en)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazine derivatives and their use as signal transduction modulators
|
CA2628039A1
(en)
|
2005-11-11 |
2007-05-18 |
Aeterna Zentaris Gmbh |
Novel pyridopyrazines and their use as modulators of kinases
|
DK1966214T3
(en)
|
2005-12-21 |
2017-02-13 |
Janssen Pharmaceutica Nv |
TRIAZOLPYRIDAZINES AS TYROSINKINASA MODULATORS
|
WO2007125405A2
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
GB0609621D0
(en)
|
2006-05-16 |
2006-06-21 |
Astrazeneca Ab |
Novel co-crystal
|
EP2029600B1
(en)
|
2006-05-24 |
2012-03-14 |
Boehringer Ingelheim International GmbH |
Substituted pteridines substituted with a four-membered heterocycle
|
TWI398252B
(en)
|
2006-05-26 |
2013-06-11 |
Novartis Ag |
Pyrrolopyrimidine compounds and their uses
|
CA2657702A1
(en)
|
2006-07-03 |
2008-01-10 |
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek E N Patieentenzorg |
Quinazolines and related heterocyclic comp0unds, and their therapeutic use
|
JP2008127446A
(en)
|
2006-11-20 |
2008-06-05 |
Canon Inc |
1,5-naphthyridine compound and organic light emitting device
|
US20110262525A1
(en)
|
2006-12-13 |
2011-10-27 |
Schering Corporation |
Methods of treatment
|
RU2009122670A
(en)
|
2006-12-21 |
2011-01-27 |
Плекссикон, Инк. (Us) |
COMPOUNDS AND METHODS FOR MODULATION OF KINASES AND INDICATIONS FOR THEIR USE
|
WO2008078091A1
(en)
|
2006-12-22 |
2008-07-03 |
Astex Therapeutics Limited |
Bicyclic heterocyclic compounds as fgfr inhibitors
|
EA200900819A1
(en)
|
2006-12-22 |
2010-02-26 |
Новартис Аг |
QUINAZOLINS FOR INHIBITION OF PDK1
|
KR20080062876A
(en)
|
2006-12-29 |
2008-07-03 |
주식회사 대웅제약 |
Novel antifungal triazole derivatives
|
US20100234386A1
(en)
|
2007-05-10 |
2010-09-16 |
Chaudhari Amita |
Quinoxaline derivatives as pi3 kinase inhibitors
|
EP1990342A1
(en)
|
2007-05-10 |
2008-11-12 |
AEterna Zentaris GmbH |
Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
|
WO2008150827A1
(en)
|
2007-05-29 |
2008-12-11 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
AR066879A1
(en)
|
2007-06-08 |
2009-09-16 |
Novartis Ag |
DERIVATIVES OF QUINOXALINE AS INHIBITORS OF THE TYPOSINE CINASA ACTIVITY OF THE JANUS CINASES
|
CN101784520B
(en)
|
2007-06-20 |
2014-07-02 |
田边三菱制药株式会社 |
Novel malonic acid sulfonamide derivative and pharmaceutical use thereof
|
JP5548123B2
(en)
|
2007-06-21 |
2014-07-16 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Polymorphs and Hydration of 6- {Difluoro [6- (1-methyl-1H-pyrazol-4-yl) [1,2,4] triazolo [4,3-b] pyridazin-3-yl] methyl} quinoline Form, salt, and production method
|
EP2173338A1
(en)
|
2007-07-06 |
2010-04-14 |
OSI Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
RU2472797C2
(en)
|
2007-08-08 |
2013-01-20 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
2-[(2-(PHENYLAMINO)-1H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)AMINO]BENZAMIDE DERIVATIVES AS IGF-IR INIBITORS FOR TREATING CANCER
|
WO2009019518A1
(en)
|
2007-08-09 |
2009-02-12 |
Astrazeneca Ab |
Pyrimidine compounds having a fgfr inhibitory effect
|
WO2009021083A1
(en)
|
2007-08-09 |
2009-02-12 |
Smithkline Beecham Corporation |
Quinoxaline derivatives as pi3 kinase inhibitors
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
CN101910152B
(en)
|
2007-11-16 |
2014-08-06 |
因塞特公司 |
4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
WO2009137378A2
(en)
|
2008-05-05 |
2009-11-12 |
Schering Corporation |
Sequential administration of chemotherapeutic agents for treatment of cancer
|
JP5351254B2
(en)
|
2008-05-23 |
2013-11-27 |
ノバルティス アーゲー |
Quinoxaline- and quinoline-carboxamide derivatives
|
JP2012509342A
(en)
|
2008-11-20 |
2012-04-19 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
Substituted pyrrolo [2,3-B] -pyridine and -pyrazine
|
WO2010084152A1
(en)
|
2009-01-21 |
2010-07-29 |
Basilea Pharmaceutica Ag |
Novel bicyclic antibiotics
|
US20110288090A1
(en)
|
2009-02-02 |
2011-11-24 |
Armstrong Donna J |
Inhibitors of AKT Activity
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
DK2440545T3
(en)
|
2009-06-12 |
2019-07-22 |
Abivax |
Compounds useful for treating cancer
|
AU2010289397B2
(en)
|
2009-09-03 |
2016-05-26 |
Bioenergenix |
Heterocyclic compounds for the inhibition of PASK
|
CN102596932A
(en)
|
2009-09-04 |
2012-07-18 |
拜耳医药股份有限公司 |
Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
|
US9095596B2
(en)
|
2009-10-15 |
2015-08-04 |
Southern Research Institute |
Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
|
US20110123545A1
(en)
|
2009-11-24 |
2011-05-26 |
Bristol-Myers Squibb Company |
Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
|
EP2332939A1
(en)
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
|
KR20130053404A
(en)
|
2010-03-30 |
2013-05-23 |
베르선 코포레이션 |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
WO2011146591A1
(en)
|
2010-05-19 |
2011-11-24 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
CA2804304C
(en)
|
2010-05-24 |
2020-02-25 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
CN102532141A
(en)
|
2010-12-08 |
2012-07-04 |
中国科学院上海药物研究所 |
(1,2,4)-triazolo-(4,3-b) (1,2,4)-triazine compounds, as well as preparation method and use thereof
|
JP5963777B2
(en)
|
2011-01-31 |
2016-08-03 |
ノバルティス アーゲー |
New heterocyclic derivatives
|
AU2012212075A1
(en)
|
2011-02-02 |
2013-07-18 |
Amgen Inc. |
Methods and compositons relating to inhibition of IGF-1R
|
JP6130305B2
(en)
|
2011-02-23 |
2017-05-17 |
インテリカイン, エルエルシー |
Combinations of kinase inhibitors and their use
|
WO2012118492A1
(en)
|
2011-03-01 |
2012-09-07 |
Array Biopharma Inc. |
Heterocyclic sulfonamides as raf inhibitors
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
PL2707361T3
(en)
|
2011-05-10 |
2018-01-31 |
Gilead Sciences Inc |
Fused heterocyclic compounds as sodium channel modulators
|
JP6002223B2
(en)
|
2011-08-26 |
2016-10-05 |
ニューファーマ, インコーポレイテッド |
Specific chemical entities, compositions and methods
|
US9518029B2
(en)
|
2011-09-14 |
2016-12-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
WO2013052699A2
(en)
|
2011-10-04 |
2013-04-11 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of pi3k
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
CN104039790B
(en)
|
2011-10-28 |
2016-04-13 |
诺华股份有限公司 |
Purine derivative and their application in disease therapy
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
JO3210B1
(en)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
Fused bicyclic oxazolidinone cetp inhibitor
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
WO2013133351A1
(en)
|
2012-03-08 |
2013-09-12 |
アステラス製薬株式会社 |
Novel fgfr3 fusion product
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
US20150203589A1
(en)
|
2012-07-24 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
CN105683197B
(en)
|
2013-08-02 |
2019-12-27 |
亚尼塔公司 |
Methods of treating various cancers using AXL/cMET inhibitors, alone or in combination with other agents
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
BR112016022062B1
(en)
|
2014-03-26 |
2023-04-11 |
Astex Therapeutics Limited |
COMBINATION, PHARMACEUTICAL COMPOSITION, USE OF A COMBINATION OR A PHARMACEUTICAL COMPOSITION, AND, PHARMACEUTICAL PRODUCT
|
JO3512B1
(en)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
Quinoxaline derivatives useful as fgfr kinase modulators
|
SI3122358T1
(en)
|
2014-03-26 |
2021-04-30 |
Astex Therapeutics Ltd. |
Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
|
JOP20200201A1
(en)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
|
WO2016134234A1
(en)
|
2015-02-19 |
2016-08-25 |
Bioclin Therapeutics, Inc. |
Methods, compositions, and kits for treatment of cancer
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|